Company IRLAB Therapeutics AB

IRLAB A

SE0012675361

Pharmaceuticals

Delayed Nasdaq Stockholm 08:15:56 2026-08-26 EDT			5-day change	1st Jan Change
1.712 ^SEK	-1.95%		+1.18%	-13.10%

04:20am	IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
01:08am	Irlab cuts revenue and operating loss	FW

Business description: IRLAB Therapeutics AB

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Number of employees: 31

Sales by Activity: IRLAB Therapeutics AB

Fiscal Period: December	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)	2025 (SEK)
Pharmaceuticals	208M	61.14M	5.68M	94.63M	57.46M

See all business segments

Geographical breakdown of sales: IRLAB Therapeutics AB

Fiscal Period: December	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)	2025 (SEK)
United States	-	-	4.22M	94.63M	57.46M
United Kingdom	208M	61.14M	1.46M	-	-

See all geographic segments

Executive Committee: IRLAB Therapeutics AB

Manager	Title	Age	Since
Kristina Torfgård CEO	Chief Executive Officer	63	2024-07-31
Susanna Waters PRN	Corporate Officer/Principal	60	2012-12-31
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	2015-12-31
Nicholas Waters CEO	Chief Executive Officer	64	2012-12-31
Gustaf Albért DFI	Director of Finance/CFO	58	2025-11-16

See IRLAB THERAPEUTICS AB governance

Composition of the Board of Directors: IRLAB Therapeutics AB

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	2015-12-31
Carola Elisabet Lemne CHM	Chairman	68	2023-02-19
Gunnar Olof Olsson CHM	Chairman	73	2020-05-06
Christer Nordstedt BRD	Director/Board Member	64	2022-12-31
Veronica Wallin BRD	Director/Board Member	40	2022-12-31
Jan-Fredrik Backman BRD	Director/Board Member	-	2026-06-04
James Gamgort BRD	Director/Board Member	-	2026-06-04

Composition of the Board of Directors

Shareholders: IRLAB Therapeutics AB

Name	Stocks	%	Valuation
ISEC Services AB 0.1103 %	161,423	0.1103 %	22 302 kr
FCG Fonder AB 0.006639 %	9,718	0.006639 %	1 343 kr

List of IRLAB THERAPEUTICS AB shareholders

Company details: IRLAB Therapeutics AB

IRLAB Therapeutics AB

Arvid Wallgrens Backe 20

413 46, Gothenburg

+46 3 17 57 38 00

http://www.irlab.se

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB	-1.95%	+1.18%	-44.51%	-78.49%	27.42M
ELI LILLY AND COMPANY	-1.06%	+0.65%	+77.42%	+122.82%	1,100B
JOHNSON & JOHNSON	+0.04%	+0.75%	+53.10%	+64.29%	658B
ABBVIE INC.	+0.48%	+2.65%	+28.06%	+81.19%	470B
ROCHE HOLDING AG	-1.06%	+0.95%	+43.09%	+43.12%	372B
NOVARTIS AG	-0.68%	+0.44%	+26.07%	+41.15%	304B
ASTRAZENECA PLC	-1.33%	+2.40%	+3.94%	+14.21%	264B
AMGEN INC.	-0.36%	+3.99%	+53.31%	+72.49%	239B
NOVO NORDISK A/S	-0.27%	+3.02%	-12.10%	-52.28%	213B
GILEAD SCIENCES, INC.	+1.38%	+3.72%	+30.33%	+93.56%	184B
Average	-0.34%	+2.74%	+25.87%	+40.21%	380.29B
Weighted average by Cap.	-0.03%	+2.21%	+45.76%	+71.33%